New Study Finds Cancer-Related Anxiety and Depression are Costing Medicare $5B Annually SAN FRANCISCO, March 31, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics today announced results from a study providing the largest and most comprehensive assessment to date of the impact of...

Blue Note Therapeutics to Present Health Economic Data at NCCN 2022 Annual Conference SAN FRANCISCO, March 24, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics today announced that new data from a health economic study of anxiety and depression in Medicare patients living with cancer...

Blue Note Therapeutics Enters Licensing Agreement With University of Sydney for ConquerFear, a Cancer Survivorship Intervention SAN FRANCISCO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced...

Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-Only Digital Therapeutic for Acute Myeloid Leukemia SAN FRANCISCO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced...